Morgan Stanley analyst Josh Baer maintains DigitalOcean Holdings (NYSE:DOCN) with a Equal-Weight and raises the price target from $60 to $92.
Spectrum Pharmaceuticals Receives FDA Approval for ROLVEDON™ (eflapegrastim-xnst) Injection
First novel Long-Acting GCSF (LA-GCSF) product approved in over 20 years
ROLVEDON™ developed using proprietary LAPSCOVERY™ technology with a differentiated molecular structure and proven safety and